AdaptImmune Therapeutics IPO Research Information

AdaptImmune Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on AdaptImmune Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
AdaptImmune Therapeutics	ADAP - NASDAQ	$15.00-$17.00	$17.00	$19.25	11.25 million	5/6/2015
Underwriter(s): BofA Merrill Lynch, Cowen & Co., Leerink Partners
Co-Manager(s): Guggenheim Securities
Industry: Health Care
Filing(s): Filed 2015-04-06 Terms Added 2015-04-27

AdaptImmune Therapeutics Quote & Chart - Click for current quote - ADAP

About AdaptImmune Therapeutics (adapted from AdaptImmune Therapeutics prospectus):
They are a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products based on their T-cell receptor platform.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "ADAP" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.